Histaminoid responses to atracurium, vecuronium and tubocurarine.
Sixty patients scheduled for elective surgery underwent intradermal testing with 0.1 ml of the following solutions diluted in 0.9% saline: vecuronium and tubocurarine (1 in 1,000), atracurium (1 in 1,000 and 1 in 10,000), thiopentone (1 in 100) and also a 0.9% saline control. Thirty minutes later, an area of erythema of greater than 1.5 cm, or a wheal exceeding 1.0 cm in diameter, was recorded as a positive reaction. The patients then randomly received equipotent doses of atracurium, vecuronium or tubocurarine during a standardized anaesthetic induction. Any cutaneous reaction and the percentage fall in systolic pressure three minutes after administration of the relaxant were recorded. In 51 patients plasma IgE levels were measured. The incidence of positive cutaneous reactions to intradermal and intravenous relaxants was significantly different with each agent (p less than 0.01). The percentage fall in systolic pressure after tubocurarine was significantly different relative to the other two agents (p less than 0.01). This was regarded as reflecting potency in releasing histamine and placed the relaxants in the same order: tubocurarine, atracurium and vecuronium. The response to intradermal administration was no guide to the subsequent response after intravenous administration of the three relaxants. IgE levels below 15 IU X ml-1 occurred significantly more often in females and were associated with a significantly higher incidence of cutaneous reactions after intradermal atracurium (1 in 1,000 and 1 in 10,000) (p less than 0.05 and 0.001 respectively) and tubocurarine (1 in 1,000). With these two agents, generalized flushing after intravenous administration was also more common in this group, relative to the normal/high IgE group.
G G
GG
Lavery
R S
RS
Clarke
J
J
Watkins
D000328:Adult; D000368:Aged; D001279:Atracurium; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology; D004890:Erythema / Q000139:chemically induced; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D007546:Isoquinolines / Q000494:pharmacology*; D008875:Middle Aged; D009466:Neuromuscular Blocking Agents / Q000494:pharmacology*; D010197:Pancuronium / Q000031:analogs & derivatives* / Q000494:pharmacology; D012882:Skin Tests; D014403:Tubocurarine / Q000494:pharmacology*; D014673:Vecuronium Bromide
D007546:Isoquinolines; D009466:Neuromuscular Blocking Agents; D001279:Atracurium; D007073:Immunoglobulin E; D014673:Vecuronium Bromide; D010197:Pancuronium; D014403:Tubocurarine